Key result
Second COVID-19 mRNA vaccine dose linked to myopericarditis in a 25-year-old man.
Why the study?
Although extremely rare, COVID-19 mRNA vaccine can induce myopericarditis without left ventricular dysfunction, with limited prior reports of such cases.
Case Report (n=1)
Highlights a rare case of myopericarditis following the second dose of a COVID-19 mRNA vaccine in a young adult, emphasizing the need for awareness of potential adverse effects.
Documents rare atypical myopericarditis post-mRNA vaccine; leaves open incidence, causality, and surveillance needs.
Although extremely rare, the COVID-19 mRNA vaccine can induce myopericarditis without left ventricular dysfunction, and there have been rare reports of such incidents. However, these prior cases either did not have pericardial effusion without reduced left ventricular ejection fraction or had a more typical presentation of vaccine-induced myopericarditis such as shortness of breath or tactile temperature. We present a rare case of a 25-year-old man who developed myopericarditis following administration of the second dose of COVID-19 mRNA Vaccine. As vaccination plays a significant role in the fight against the COVID-19 pandemic, it is essential to highlight the physical manifestations of the vaccine's potential adverse effects and risk factors to increase the general population's awareness regarding the importance of emergent medical care.
No takes yet. Share an insight, caveat, or question.
Sharbatdaran et al. (2022) conducted a case report in COVID-19 vaccine-induced myopericarditis (n=1). COVID-19 mRNA Vaccine was evaluated on myopericarditis. A 25-year-old man developed myopericarditis following administration of the second dose of a COVID-19 mRNA vaccine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: